Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

[Prevalence of cognitive impairment in a high social risk population older then 60 years from Neuquén capital, Argentina].

Regueiro M, Homar C, Cañás M, Tosello V.

Vertex. 2018 May;XXIX(139):178-183. Spanish.

PMID:
30778407
2.

A Novel t(8;14)(q24;q11) Rearranged Human Cell Line as a Model for Mechanistic and Drug Discovery Studies of NOTCH1-Independent Human T-Cell Leukemia.

Tosello V, Milani G, Martines A, Macri N, Van Loocke W, Matthijssens F, Buldini B, Minuzzo S, Bongiovanni D, Schumacher RF, Amadori A, Van Vlierberghe P, Piovan E.

Cells. 2018 Oct 9;7(10). pii: E160. doi: 10.3390/cells7100160.

3.

Chemotactic Cues for NOTCH1-Dependent Leukemia.

Piovan E, Tosello V, Amadori A, Zanovello P.

Front Immunol. 2018 Apr 3;9:633. doi: 10.3389/fimmu.2018.00633. eCollection 2018. Review.

4.

WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia.

Bordin F, Piovan E, Masiero E, Ambesi-Impiombato A, Minuzzo S, Bertorelle R, Sacchetto V, Pilotto G, Basso G, Zanovello P, Amadori A, Tosello V.

Haematologica. 2018 Feb;103(2):266-277. doi: 10.3324/haematol.2017.170431. Epub 2017 Nov 23.

5.
6.

Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein degradation.

Tosello V, Bordin F, Yu J, Agnusdei V, Indraccolo S, Basso G, Amadori A, Piovan E.

Leukemia. 2016 Apr;30(4):812-22. doi: 10.1038/leu.2015.335. Epub 2015 Dec 9.

PMID:
26648536
7.

Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.

Herranz D, Ambesi-Impiombato A, Sudderth J, Sánchez-Martín M, Belver L, Tosello V, Xu L, Wendorff AA, Castillo M, Haydu JE, Márquez J, Matés JM, Kung AL, Rayport S, Cordon-Cardo C, DeBerardinis RJ, Ferrando AA.

Nat Med. 2015 Oct;21(10):1182-9. doi: 10.1038/nm.3955. Epub 2015 Sep 21.

8.

DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.

Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, Tallman JE, Zhao X, Daniels D, Dai Q, Ciminio L, Aifantis I, He C, Fuks F, Tallman MS, Ferrando A, Nimer S, Paietta E, Thompson CB, Licht JD, Mason CE, Godley LA, Melnick A, Figueroa ME, Levine RL.

Cell Rep. 2014 Dec 11;9(5):1841-1855. doi: 10.1016/j.celrep.2014.11.004. Epub 2014 Dec 4.

9.

Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.

Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, Sanchez-Martin M, Perez-Garcia A, Rigo I, Castillo M, Indraccolo S, Cross JR, de Stanchina E, Paietta E, Racevskis J, Rowe JM, Tallman MS, Basso G, Meijerink JP, Cordon-Cardo C, Califano A, Ferrando AA.

Cancer Cell. 2013 Dec 9;24(6):766-76. doi: 10.1016/j.ccr.2013.10.022. Epub 2013 Nov 27.

10.

The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy.

Tosello V, Ferrando AA.

Ther Adv Hematol. 2013 Jun;4(3):199-210. doi: 10.1177/2040620712471368.

11.

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.

Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, Paietta E, Racevskis J, Rowe JM, Tallman MS, Paganin M, Basso G, Hof J, Kirschner-Schwabe R, Palomero T, Rabadan R, Ferrando A.

Nat Med. 2013 Mar;19(3):368-71. doi: 10.1038/nm.3078. Epub 2013 Feb 3.

12.

Targeting nonclassical oncogenes for therapy in T-ALL.

Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, Kashishian A, Thompson MA, Castillo M, Cordon-Cardo C, Davé UP, Ferrando A, Lannutti BJ, Diacovo TG.

Cancer Cell. 2012 Apr 17;21(4):459-72. doi: 10.1016/j.ccr.2012.02.029.

13.

ETV6 mutations in early immature human T cell leukemias.

Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, Hadler M, Tosello V, Della Gatta G, Paietta E, Racevskis J, Wiernik PH, Luger SM, Rowe JM, Rue M, Ferrando AA.

J Exp Med. 2011 Dec 19;208(13):2571-9. doi: 10.1084/jem.20112239. Epub 2011 Dec 12.

14.

Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.

Masiero M, Minuzzo S, Pusceddu I, Moserle L, Persano L, Agnusdei V, Tosello V, Basso G, Amadori A, Indraccolo S.

Leukemia. 2011 Apr;25(4):588-98. doi: 10.1038/leu.2010.323. Epub 2011 Jan 25.

PMID:
21263446
15.

The TLX1 oncogene drives aneuploidy in T cell transformation.

De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, Van Vlierberghe P, Barnes K, Castillo M, Sole X, Hadler M, Lenz J, Aplan PD, Kelliher M, Kee BL, Pandolfi PP, Kappes D, Gounari F, Petrie H, Van der Meulen J, Speleman F, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Soulier J, Avran D, Cavé H, Dastugue N, Raimondi S, Meijerink JP, Cordon-Cardo C, Califano A, Ferrando AA.

Nat Med. 2010 Nov;16(11):1321-7. doi: 10.1038/nm.2246. Epub 2010 Oct 24.

16.

Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.

Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, Protopopov A, Tosello V, Kutok J, Larson RS, Borowitz MJ, Loh ML, Ferrando AA, Winter SS, Mullighan CG, Silverman LB, Chin L, Hunger SP, Sallan SE, Look AT.

J Clin Oncol. 2010 Aug 20;28(24):3816-23. doi: 10.1200/JCO.2010.28.3390. Epub 2010 Jul 19.

17.

WT1 mutations in T-ALL.

Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JP, Ferrando AA.

Blood. 2009 Jul 30;114(5):1038-45. doi: 10.1182/blood-2008-12-192039. Epub 2009 Jun 3.

18.

Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.

Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C, Homminga I, Meijerink J, Aifantis I, Basso G, Cordon-Cardo C, Ai W, Ferrando A.

Nat Med. 2009 Jan;15(1):50-8. doi: 10.1038/nm.1900. Epub 2008 Dec 21.

19.

Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4.

Tosello V, Zamarchi R, Merlo A, Gorza M, Piovan E, Mandruzzato S, Bronte V, Wang X, Ferrone S, Amadori A, Zanovello P.

Eur J Immunol. 2009 Jan;39(1):56-66. doi: 10.1002/eji.200738098.

20.

The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects.

Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, Miotti S, Tosello V, Zamarchi R, Corradin A, Minuzzo S, Rossi E, Basso G, Amadori A.

Cancer Res. 2008 Jul 15;68(14):5658-68. doi: 10.1158/0008-5472.CAN-07-6341.

21.

NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL.

Sulis ML, Williams O, Palomero T, Tosello V, Pallikuppam S, Real PJ, Barnes K, Zuurbier L, Meijerink JP, Ferrando AA.

Blood. 2008 Aug 1;112(3):733-40. doi: 10.1182/blood-2007-12-130096. Epub 2008 Apr 14.

22.

Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs.

Tosello V, Odunsi K, Souleimanian NE, Lele S, Shrikant P, Old LJ, Valmori D, Ayyoub M.

Clin Immunol. 2008 Mar;126(3):291-302. doi: 10.1016/j.clim.2007.11.008. Epub 2007 Dec 31.

PMID:
18166500
23.

Differential regulation of hypoxia-induced CXCR4 triggering during B-cell development and lymphomagenesis.

Piovan E, Tosello V, Indraccolo S, Masiero M, Persano L, Esposito G, Zamarchi R, Ponzoni M, Chieco-Bianchi L, Dalla-Favera R, Amadori A.

Cancer Res. 2007 Sep 15;67(18):8605-14.

24.

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52. Epub 2007 May 15.

25.

Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen.

Valmori D, Lévy F, Godefroy E, Scotto L, Souleimanian NE, Karbach J, Tosello V, Hesdorffer CS, Old LJ, Jager E, Ayyoub M.

Clin Immunol. 2007 Feb;122(2):163-72. Epub 2006 Oct 24.

PMID:
17064965
27.

Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.

Indraccolo S, Stievano L, Minuzzo S, Tosello V, Esposito G, Piovan E, Zamarchi R, Chieco-Bianchi L, Amadori A.

Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4216-21. Epub 2006 Mar 6.

28.
29.

Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition.

Indraccolo S, Tisato V, Tosello V, Habeler W, Esposito G, Moserle L, Stievano L, Persano L, Chieco-Bianchi L, Amadori A.

Hum Gene Ther. 2005 Aug;16(8):957-70.

PMID:
16076254
30.

CD40 activation of B-CLL cells is associated with augmented intracellular levels of CD79b and increased BCR expression in a subset of patients.

Minuzzo S, Indraccolo S, Tosello V, Piovan E, Cabrelle A, Trentin L, Semenzato G, Amadori A.

Leukemia. 2005 Jun;19(6):1099-101. No abstract available.

PMID:
15830006
31.

Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation.

Piovan E, Tosello V, Indraccolo S, Cabrelle A, Baesso I, Trentin L, Zamarchi R, Tamamura H, Fujii N, Semenzato G, Chieco-Bianchi L, Amadori A.

Blood. 2005 Feb 1;105(3):931-9. Epub 2004 Sep 28.

32.

Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.

Rosato A, Zoso A, Milan G, Macino B, Dalla Santa S, Tosello V, Di Carlo E, Musiani P, Whalen RG, Zanovello P.

J Immunol. 2003 Nov 15;171(10):5172-9.

33.

CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes.

Stievano L, Tosello V, Marcato N, Rosato A, Sebelin A, Chieco-Bianchi L, Amadori A.

J Immunol. 2003 Nov 1;171(9):4528-38.

34.

Tumor outgrowth in peripheral blood mononuclear cell-injected SCID mice is not associated with early Epstein-Barr virus reactivation.

Piovan E, Bonaldi L, Indraccolo S, Tosello V, Menin C, Comacchio F, Chieco-Bianchi L, Amadori A.

Leukemia. 2003 Aug;17(8):1643-9.

PMID:
12886254
35.

Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice.

Roni V, Habeler W, Parenti A, Indraccolo S, Gola E, Tosello V, Cortivo R, Abatangelo G, Chieco-Bianchi L, Amadori A.

Exp Cell Res. 2003 Jul 1;287(1):28-38.

PMID:
12799179
36.

The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.

Rosato A, Dalla Santa S, Zoso A, Giacomelli S, Milan G, Macino B, Tosello V, Dellabona P, Lollini PL, De Giovanni C, Zanovello P.

Cancer Res. 2003 May 1;63(9):2158-63.

37.

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.

Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P.

J Immunol. 2003 Jan 1;170(1):270-8.

38.

Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors.

Indraccolo S, Habeler W, Tisato V, Stievano L, Piovan E, Tosello V, Esposito G, Wagner R, Uberla K, Chieco-Bianchi L, Amadori A.

Cancer Res. 2002 Nov 1;62(21):6099-107.

39.

Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient.

Mandruzzato S, Rossi E, Bernardi F, Tosello V, Macino B, Basso G, Chiarion-Sileni V, Rossi CR, Montesco C, Zanovello P.

J Immunol. 2002 Oct 1;169(7):4017-24.

40.

Expression and functional activity of CXCR-4 and CCR-5 chemokine receptors in human thymocytes.

Zamarchi R, Allavena P, Borsetti A, Stievano L, Tosello V, Marcato N, Esposito G, Roni V, Paganin C, Bianchi G, Titti F, Verani P, Gerosa G, Amadori A.

Clin Exp Immunol. 2002 Feb;127(2):321-30.

41.

Expression from cell type-specific enhancer-modified retroviral vectors after transduction: influence of marker gene stability.

Indraccolo S, Roni V, Zamarchi R, Roccaforte F, Minuzzo S, Stievano L, Habeler W, Marcato N, Tisato V, Tosello V, Chieco-Bianchi L, Amadori A.

Gene. 2002 Jan 23;283(1-2):199-208.

PMID:
11867226
42.

Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors.

Indraccolo S, Minuzzo S, Roccaforte F, Zamarchi R, Habeler W, Stievano L, Tosello V, Klein D, Günzburg WH, Basso G, Chieco-Bianchi L, Amadori A.

Blood. 2001 Dec 15;98(13):3607-17.

43.

Beat-to-beat oscillations of mitochondrial [Ca2+] in cardiac cells.

Robert V, Gurlini P, Tosello V, Nagai T, Miyawaki A, Di Lisa F, Pozzan T.

EMBO J. 2001 Sep 3;20(17):4998-5007.

44.

Recombinant aequorin and green fluorescent protein as valuable tools in the study of cell signalling.

Chiesa A, Rapizzi E, Tosello V, Pinton P, de Virgilio M, Fogarty KE, Rizzuto R.

Biochem J. 2001 Apr 1;355(Pt 1):1-12. Review.

45.

Recombinant aequorin as tool for monitoring calcium concentration in subcellular compartments.

Robert V, Pinton P, Tosello V, Rizzuto R, Pozzan T.

Methods Enzymol. 2000;327:440-56. No abstract available.

PMID:
11045002
46.

Alteration in calcium handling at the subcellular level in mdx myotubes.

Robert V, Massimino ML, Tosello V, Marsault R, Cantini M, Sorrentino V, Pozzan T.

J Biol Chem. 2001 Feb 16;276(7):4647-51. Epub 2000 Oct 11.

Supplemental Content

Loading ...
Support Center